Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence

Abstract

Senescence is a tumor suppression mechanism defined by stable proliferation arrest. Here we demonstrate that the known synthetic lethal interaction between poly(ADP-ribose) polymerase 1 inhibitors (PARPi) and DNA repair triggers p53-independent ovarian cancer cell senescence defined by senescence-associated phenotypic hallmarks including DNA-SCARS, inflammatory secretome, Bcl-XL-mediated apoptosis resistance, and proliferation restriction via Chk2 and p21 (CDKN1A). The concept of senescence as irreversible remains controversial and here we show that PARPi-senescent cells re-initiate proliferation upon drug withdrawal, potentially explaining the requirement for sustained PARPi therapy in the clinic. Importantly, PARPi-induced senescence renders ovarian and breast cancer cells transiently susceptible to second-phase synthetic lethal approaches targeting the senescence state using senolytic drugs. The combination of PARPi and a senolytic is effective in preclinical models of ovarian and breast cancer suggesting that coupling these synthetic lethalities provides a rational approach to their clinical use and may together be more effective in limiting resistance.

References 57

1. 1.

   Rodriguez MI, et al. Deciphering the insights of poly(ADP-ribosylation) in tumor progression. Med. Res. Rev. 2015;35:678-697.

   Not in our library10.1002/med.21339

2. 2.

   Wang YQ, et al. An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy. J. Med. Chem. 2016;59:9575-9598.

   Not in our library10.1021/acs.jmedchem.6b00055

3. 3.

   Ledermann J, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New Engl. J. Med. 2012;366:1382-1392.

   Not in our library10.1056/nejmoa1105535

4. 4.

   Fleury H, et al. Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines. Oncotarget. 2017;8:40152-40168.

   Not in our library10.18632/oncotarget.10308

5. 5.

   Dulaney C, Marcrom S, Stanley J, Yang ES. Poly(ADP-ribose) polymerase activity and inhibition in cancer. Semin. Cell Dev. Biol. 2017;63:144-153.

   Not in our library10.1016/j.semcdb.2017.01.007

6. 6.

   O’Sullivan Coyne G, Chen AP, Meehan R, Doroshow JH. PARP inhibitors in reproductive system cancers: current use and developments. Drugs. 2017;77:113-130.

   Not in our library10.1007/s40265-016-0688-7

7. 7.

   Pommier Y, O’Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci. Transl. Med. 2016;8:362ps317.

   Not in our library10.1126/scitranslmed.aaf9246

8. 8.

   Rodier F, Campisi J. Four faces of cellular senescence. J. Cell Biol. 2011;192:547-556.

   Not in our library10.1083/jcb.201009094

9. 9.

   Beausejour CM, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 2003;22:4212-4222.

   Not in our library10.1093/emboj/cdg417

10. 10.

    Gonzalez LC, Ghadaouia S, Martinez A, Rodier F. Premature aging/senescence in cancer cells facing therapy: good or bad? Biogerontology. 2016;17:71-87.

    Not in our library10.1007/s10522-015-9593-9

11. 11.

    Alotaibi M, et al. Radiosensitization by PARP Inhibition in DNA repair proficient and deficient tumor cells: proliferative recovery in senescent cells. Radiat. Res. 2016;185:229-245.

    Not in our library10.1667/rr14202.1

12. 12.

    Chitikova ZV, et al. Sustained activation of DNA damage response in irradiated apoptosis-resistant cells induces reversible senescence associated with mTOR downregulation and expression of stem cell markers. Cell Cycle. 2014;13:1424-1439.

    Not in our library10.4161/cc.28402

13. 13.

    Baker DJ, Alimirah F, van Deursen JM, Campisi J, Hildesheim J. Oncogenic senescence: a multi-functional perspective. Oncotarget. 2017;8:27661-27672.

    Not in our library10.18632/oncotarget.15742

14. 14.

    Le Duff M, et al. Regulation of senescence escape by the cdk4-EZH2-AP2M1 pathway in response to chemotherapy. Cell Death Dis. 2018;9:199.

    Not in our library10.1038/s41419-017-0209-y

15. 15.

    Malaquin N, Martinez A, Rodier F. Keeping the senescence secretome under control: Molecular reins on the senescence-associated secretory phenotype. Exp. Gerontol. 2016;82:39-49.

    Not in our library10.1016/j.exger.2016.05.010

16. 16.

    Ritschka B, et al. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes Dev. 2017;31:172-183.

    Not in our library10.1101/gad.290635.116

17. 17.

    Milanovic M, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553:96-100.

    Not in our library10.1038/nature25167

18. 18.

    Chang J, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 2016;22:78-83.

    Not in our library10.1038/nm.4010

19. 19.

    Wang L, et al. High-throughput functional genetic and compound screens identify targets for senescence induction in cancer. Cell Rep. 2017;21:773-783.

    Not in our library10.1016/j.celrep.2017.09.085

20. 20.
    Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL · 2016

    No notice
21. 21.
    Identification of a novel senolytic agent, navitoclax, targeting the Bcl‐2 family of anti‐apoptotic factors · 2016

    No notice
22. 22.

    Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615.

    Not in our library10.1038/nature10166

23. 23.

    Fleury H, et al. Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease. Genes Cancer. 2015;6:378-398.

    Not in our library10.18632/genesandcancer.76

24. 24.

    Letourneau IJ, et al. Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. BMC Cancer. 2012;12:379.

    Not in our library10.1186/1471-2407-12-379

25. 25.
    Characterization of three new serous epithelial ovarian cancer cell lines · 2008

    Not checked
26. 26.

    Provencher D. M., Lounis H., Champoux L., Tétrault M., Manderson E. N., Wang J. C., Eydoux P., Savoie R., Tonin P. N., Mes-Masson A.-M. CHARACTERIZATION OF FOUR NOVEL EPITHELIAL OVARIAN CANCER CELL LINES. In Vitro Cellular and Developmental Biology--Animal. 2000;36(6):357-361.

    Not in our library10.1290/1071-2690(2000)036<0357:cofneo>2.0.co;2

27. 27.
    DDR-mediated crosstalk between DNA-damaged cells and their microenvironment · 2015

    Not checked
28. 28.

    Coppe JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 2010;5:99-118.

    Not in our library10.1146/annurev-pathol-121808-102144

29. 29.

    Dimri GP, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA. 1995;92:9363-9367.

    Not in our library10.1073/pnas.92.20.9363

30. 30.

    Jelinic P, Levine DA. New insights into PARP inhibitors’ effect on cell cycle and homology-directed DNA damage repair. Mol. Cancer Ther. 2014;13:1645-1654.

    Not in our library10.1158/1535-7163.mct-13-0906-t

31. 31.

    de Bono Johann, Ramanathan Ramesh K., Mina Lida, Chugh Rashmi, Glaspy John, Rafii Saeed, Kaye Stan, Sachdev Jasgit, Heymach John, Smith David C., Henshaw Joshua W., Herriott Ashleigh, Patterson Miranda, Curtin Nicola J., Byers Lauren Averett, Wainberg Zev A. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discovery. 2017;7(6):620-629.

    Not in our library10.1158/2159-8290.cd-16-1250

32. 32.

    Mirza MR, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New Engl. J. Med. 2016;375:2154-2164.

    Not in our library10.1056/nejmoa1611310

33. 33.

    Storer M, et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell. 2013;155:1119-1130.

    Not in our library10.1016/j.cell.2013.10.041

34. 34.

    Aliouat-Denis CM, et al. p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2. Mol. Cancer Res. 2005;3:627-634.

    Not in our library10.1158/1541-7786.mcr-05-0121

35. 35.

    Ryu SJ, Oh YS, Park SC. Failure of stress-induced downregulation of Bcl-2 contributes to apoptosis resistance in senescent human diploid fibroblasts. Cell Death Differ. 2007;14:1020-1028.

    Not in our library10.1038/sj.cdd.4402091

36. 36.

    Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat. Rev. Drug Discov. 2017;16:273-284.

    Not in our library10.1038/nrd.2016.253

37. 37.
    New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463 · 2017

    No notice
38. 38.

    Bansal M, et al. A community computational challenge to predict the activity of pairs of compounds. Nat. Biotechnol. 2014;32:1213-1222.

    Not in our library10.1038/nbt.3052

39. 39.
    Cellular Senescence: A Translational Perspective · 2017

    Not checked
40. 40.

    Szekely B, Silber AL, Pusztai L. New therapeutic strategies for triple-negative breast cancer. Oncology. 2017;31:130-137.

    Not in our library

Cited by papers we hold 8

• Metabolic landscape in cardiac aging: insights into molecular biology and therapeutic implications · 2023
  No notice
• Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma · 2023
  No notice
• Overcoming the senescence‐associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer · 2021
  No notice
• Therapy-Induced Senescence: An “Old” Friend Becomes the Enemy · 2020
  No notice
• Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies · 2020
  No notice
• Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation · 2020
  No notice
• Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X L –BAX interaction · 2020
  No notice
• DNA Methyltransferases in Cancer: Biology, Paradox, Aberrations, and Targeted Therapy · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.